Quarterly and annual results disclosed under 8-K Item 2.02.
XWELL, Inc. reported financial results for the first quarter ended March 31, 2024.
“On May 15, 2024, XWELL, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024, and provided a corporate update.”
Venus Concept Inc. reported financial results for the three months ended March 31, 2024.
“Venus Concept Inc. issued a press release relating to its financial results for the three months ended March 31, 2024.”
Progressive Care Inc. reported the three months ended March 31, 2024 results: revenue approximately $14.6 million.
“Progressive Care Inc. Announces Record First Quarter 2024 Revenues of $14.6 Million”
Sagimet Biosciences Inc. reported the quarter ended March 31, 2024 results: net income Net loss for the first quarter ended March 31, 2024 was $6.6 million compared to a net loss of $6.6 million for the firs.
“today reported financial results for the quarter ended March 31, 2024”
AYTU BIOPHARMA, INC reported fiscal 2024 third quarter results: revenue $18.0 million, net income $2.9 million, EPS $0.52 per share.
“on commercializing novel therapeutics, today announced financial and operational results for the fiscal 2024 third quarter. Q3 2024 Highlights ● Consolidated net revenue was $18.0 million versus $22.7 million in the prior year period and reflects the Company’s continued planned wind down of its Consumer Health Segment. ● ADHD Portfolio (Adzenys XR-ODT® and”
Luvu Brands, Inc. reported financial results for third fiscal quarter and nine months ended March 31, 2024.
“On May 15, 2024, Luvu Brands, Inc. (the “Company”) issued a press release announcing its financial results for the third fiscal quarter and nine months ended March 31, 2024”
Kartoon Studios, Inc. updated its first quarter ended March 31, 2024 guidance (reaffirmed).
“On May 15, 2024, Kartoon Studios, Inc. (the “Company”) issued an earnings release announcing, among other things, the Company’s operational highlights for the first quarter ended March 31, 2024.”
22nd Century Group, Inc. reported the first quarter ended March 31, 2024 results: revenue $6.5 million.
“to $2.3 million, as compared to the prior comparative period of $17.5 million, and fourth quarter 2023 of $4.8 million. ● Net revenue from continuing operations was $6.5 million, as the Company further refined its revenue mix away from negative margin filtered cigars in favor of higher margin VLN ® and conventional cigarettes. ● Gross profit for the”
OMEROS CORP reported the first quarter ended March 31, 2024 results: net income Net loss for the first quarter of 2024 was $37.2 million, or $0.63 per share, EPS $0.63 per share.
“Omeros Corporation Reports First Quarter 2024 Financial Results”
BATTALION OIL CORP reported the first quarter of 2024 results: revenue $49.9 million, net income a net loss available to common stockholders of $36.8 million, EPS a net loss of $2.24 per share available to common stockholders.
“per month in gas treating costs. Results of Operations Average daily net production and total operating revenue during the first quarter of 2024 were 12,989 Boe/d (48% oil) and $49.9 million, respectively, as compared to production and revenue of 16,200 Boe/d (50% oil) and $65.1 million, respectively, during the first quarter of 2023. The decrease in revenues in the”
AGILE THERAPEUTICS INC reported three months ended March 31, 2024 results: revenue $5.7 million, net income $1.3 million, EPS $0.28 per share.
“Net Revenue: In the first quarter 2024, the Company realized net product sales revenue of $5.7 million, a 58% increase from the fourth quarter 2023 and an increase of 50% as compared to the first quarter of 2023 net revenue of $3.8 million. ● Cost of Goods Sold (COGS) : Cost of goods sold, which consists of direct and indirect costs related to the manufacturing of Twirla, were $1.7 million for the first quarter 2024 compared to the $2.2 million for the fourth quarter 2023 and compared to the $2.0 million for the first quarter 2023. ● Total operating expenses: Total GAAP operating expenses were $6.8 million for the quarter ended March 31, 2024, compared to the $5.5 million for the fourth quarter 2023 and compared to $8.5 million for the comparable period in 2023 – a decrease of 20%. ● GAAP Net income (loss): GAAP net income was $1.3 million, or $0.28 per share, for the quarter ended March 31, 2024, compared to a GAAP net loss of $4.5 million, or $1.51 per share, for the fourth quarter 2”
Big Digital Energy, Inc. reported first quarter of fiscal year 2024 ended March 31, 2024 results: revenue $18.77 million.
“Q1 2024 revenue increased 145% Y/Y and 34% Q/Q to $18.77 million.”
Molecular Templates, Inc. reported the first quarter of 2024 ended March 31, 2024 results: revenue $11.1 million, net income $0.6 million, EPS $0.11 per basic share and $0.08 per diluted share.
“a net income attributable to common shareholders of $10.8 million, or $2.89 per basic and diluted share, for the same period in 2023. Revenues for the first quarter of 2024 were $11.1 million, compared to $36.6 million for the same period in 2023. Total research and development expenses for the first quarter of 2024 were $7.4 million, compared with $19.0 million for”
PEDEVCO CORP reported three months ended March 31, 2024 results: revenue $8.12 million, net income $0.8 million, EPS $0.01 per basic and diluted share outstanding.
“barrels of oil equivalent per day ("BOEPD") (84% liquids) in the three months ended March 31, 2024 (“Q1 2024”), compared to 1,428 BOEPD produced in Q1 2023. · Q1 2024 revenue of $8.12 million, decreasing $48,000 from Q1 2023. · Operating income of $0.6 million, decreasing 62% from Q1 2023. · Operating expenses (inclusive of general and administrative expenses,”
BIO-PATH HOLDINGS, INC. reported first quarter ended March 31, 2024 results: net income $3.2 million, or $4.88 per share, EPS $4.88 per share.
“The Company reported a net loss of $3.2 million, or $4.88 per share, for the three months ended March 31, 2024, compared to a net loss of $5.3 million, or $13.25 per share, for the three months ended March 31, 2023.”
LUMOS PHARMA, INC. reported the quarter ended March 31, 2024 results: net income $10.4 million.
“Net Loss – The net loss for the quarter ended March 31, 2024, was $10.4 million compared to a net loss of $7.3 million for the same period in 2023.”
GALECTIN THERAPEUTICS INC reported the quarter ended March 31, 2024 results: net income net loss of $11.5 million, EPS ($0.19) per share.
“For the quarter ended quarter ended March 31, 2024, the Company reported a net loss applicable to common stockholders of $11.5 million, or ($0.19) per share, compared to a net loss applicable to common stockholders of $11.5 million, or ($0.19) per share for the quarter ended March 31, 2023.”
YIELD10 BIOSCIENCE, INC. reported financial results for the three months ended March 31, 2024.
“On May 15, 2024, Yield10 Bioscience, Inc. issued a press release announcing the financial results for the three months ended March 31, 2024.”
Marker Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.
“Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today reported corporate updates and financial results for the first quarter ended March 31, 2024.”
PLUS THERAPEUTICS, INC. reported the first quarter ended March 31, 2024 results: revenue $1.7 million in grant revenue, net income $3.3 million, EPS $(0.75) per share.
“FIRST QUARTER 2024 FINANCIAL RESULTS • The Company’s cash balance was $3 million at March 31, 2024 compared to $8.6 million at December 31, 2023. • The Company recognized $1.7 million in grant revenue in the first quarter of 2024 compared to $0.5 million in the first quarter of 2023, which represents CPRIT’s share of the costs incurred for the Company’s rhenium ( 186 Re) obisbemeda development for the treatment of patients with LM • Total operating loss for the first quarter of 2024 was $3.3 million compared to $4.8 million in the same period of 2023. The decrease was primarily due to increased grant revenue • Net loss for first quarter of 2024 was $3.3 million, or $(0.75) per share, compared to a net loss of $4.8 million, or $(2.07) per share, for the same period the prior year”
Usio, Inc. updated its first quarter ended March 31, 2024 guidance (reaffirmed).
“On May 15, 2024, Usio, Inc. issued a press release announcing financial results for its quarter ended March 31, 2024.”
NATURAL GAS SERVICES GROUP INC reported three months ended March 31, 2024 results: revenue $33.7 million, net income $5.1 million, EPS $0.41 per basic share.
“technology and services to the energy industry, today announced financial results for the three months ended March 31, 2024. First Quarter 2024 Highlights • Rental revenue of $33.7 million, an increase of 48% when compared to the first quarter of 2023 and 7% when compared to the fourth quarter of 2023. • Net income of $5.1 million, or $0.41 per basic share, as”
NATURAL GAS SERVICES GROUP INC reported first quarter ended March 31, 2024 results: revenue $33.7 million, net income $5.1 million, EPS $0.41 per basic share.
“technology and services to the energy industry, today announced financial results for the three months ended March 31, 2024. First Quarter 2024 Highlights • Rental revenue of $33.7 million, an increase of 48% when compared to the first quarter of 2023 and 7% when compared to the fourth quarter of 2023. • Net income of $5.1 million, or $0.41 per basic share, as”
Presidio Property Trust, Inc. reported three months ended March 31, 2024 results: revenue $4.8 million, net income approximately $5.8 million, EPS ($0.47) per basic and diluted share.
“for the three months ended March 31, 2023. The change in net income attributable to the Company’s common stockholders was a result of: ● Total revenues were approximately $4.8 million for the three months ended March 31, 2024, compared to approximately $4.1 million for the same period in 2023. As of March 31, 2024, we had approximately $135.3 million in net”
CervoMed Inc. reported first quarter ended March 31, 2024 results: net income approximately $2.5 million.
“Net income was approximately $2.5 million for the three months ended March 31, 2024”
NextPlat Corp reported the first fiscal quarter ended March 31, 2024 results: revenue approximately $17.5 million, net income approximately $1.5 million, or ($0.08) per diluted share.
“NextPlat Reports Record Consolidated Q1 2024 Revenues of $17.5 Million Compared to $2.9 Million in Q1 2023 (508% Increase)”
STRATA Skin Sciences, Inc. reported the first fiscal quarter ended March 31, 2024 results: revenue $6.8 million, net income Net loss of $3.4 million, EPS net loss of $0.10 per basic and diluted common share.
“announces its financial results for the quarter ended March 31, 2024 and provides a corporate update. First Quarter 2024 Highlights • Revenue in the first quarter of 2024 was $6.8 million (-11% YOY) vs. $7.6 million in the first quarter of 2023 o Global net recurring revenue in the first quarter of 2024 was $4.7 million (-10% YOY) vs. $5.2 million in the first”
Panbela Therapeutics, Inc. reported the quarter ended March 31, 2024 results: net income Net loss in the quarter was approximately $7.1 million, or $2.28 per diluted share, EPS $2.28 per diluted share.
“Net loss in the quarter was approximately $7.1 million, or $2.28 per diluted share, compared to a net loss of $5.1 million, or $392.76 per diluted share, in the same period last year.”
UNITED STATES ANTIMONY CORP reported first quarter of 2024 results: revenue $2.83 million, net income $86k.
“Corporation”), (NYSE American: UAMY) reports today its first quarter 2024 financial and operational results. Revenues for the first quarter of 2024 increased 28%, or $621k, to $2.83 million, compared to the first quarter of 2023, while cost of sales only increased 11%, or $192k, during the same period. This in-turn allowed gross profit to increase 108%, or $428k,”
Wilhelmina International, Inc. reported financial results for first quarter ended March 31, 2024.
“On May 15, 2024, Wilhelmina International, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2024.”
PARKERVISION INC reported the three months ended March 31, 2024 results: net income net loss for the first quarter of 2024 of $0.7 million, or $0.01 per common share, EPS $0.01 per common share.
“ParkerVision reported a net loss for the first quarter of 2024 of $0.7 million, or $0.01 per common share, compared to net income of $13.1 million, or $0.16 per common share for the first quarter of 2023.”
Genasys Inc. reported the fiscal quarter ended March 31, 2024 results: revenue $5.7 million, net income ($6.9) million, EPS ($0.16).
“of the software business rapidly growing. We are more confident in the long-term health of our business than we have ever been.” Fiscal 2Q 2024 Financial Summary ● Revenue of $5.7 million, versus $11.2 million in 2Q 2023 ● GAAP operating loss of ($6.9) million, versus ($3.4) million in 2Q 2023. ● GAAP net loss of ($6.9) million versus ($3.4) million in 2Q 2023.”
BioCardia, Inc. reported first quarter of 2024 results: revenue approximately $55,000.
“Revenues were approximately $55,000 for the three months ended March 2024, compared to approximately $64,000 for the three months ended March 2023.”
STRATUS PROPERTIES INC reported first-quarter 2023 results: revenue $5.8 million, net income $(5.8) million, EPS $(0.73) per diluted share.
“Net income attributable to common stockholders totaled $4.6 million, or $0.56 per diluted share, in first-quarter 2024, compared to net loss attributable to common stockholders of $(5.8) million, or $(0.73) per diluted share, in first-quarter 2023. • Revenues for first-quarter 2024 were $26.5 million compared to revenues of $5.8 million for first-quarter 2023”
STRATUS PROPERTIES INC reported first-quarter 2024 results: revenue $26.5 million, net income $4.6 million, EPS $0.56 per diluted share.
“Net income attributable to common stockholders totaled $4.6 million, or $0.56 per diluted share, in first-quarter 2024, compared to net loss attributable to common stockholders of $(5.8) million, or $(0.73) per diluted share, in first-quarter 2023. • Revenues for first-quarter 2024 were $26.5 million compared to revenues of $5.8 million for first-quarter 2023”
Aptose Biosciences Inc. reported financial results for first quarter ended March 31, 2024.
“Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced financial results for the first quarter ended March 31, 2024.”
DELCATH SYSTEMS, INC. reported the first quarter ended March 31, 2024 results: revenue $3.1 million.
“Total revenue for the quarter ended March 31, 2024 was $3.1 million compared to $0.6 million for the same period in the prior year from our sales of HEPZATO in the U.S. and CHEMOSAT in Europe.”
INNOVATIVE SOLUTIONS & SUPPORT INC reported second quarter of fiscal 2024 quarter ended March 31, 2024 results: revenue $10.7 million, net income $1.2 million, EPS $0.07 per share.
“Innovative Solutions & Support, Inc. (“IS&S” or the “Company”) (NASDAQ: ISSC) today announced its financial results for the second quarter of fiscal 2024, which ended March 31, 2024. For the second quarter of fiscal 2024, IS&S reported net sales of $10.7 million, up 46% from $7.3 million in the second quarter a year ago. The Company reported net income of $1.2 million, or $0.07 per share, compared to net income of $1.3 million, or $0.07 per share, in the second quarter of fiscal 2023.”
ATLANTIC AMERICAN CORP reported first quarter ended March 31, 2024 results: revenue $44.6 million, net income net loss of $2.0 million, or ($0.10) per common share, EPS ($0.10) per common share.
“coupled with unfavorable loss experience in the life and health operations. Premium revenue for the three month period ended March 31, 2024 decreased $1.5 million, or 3.4%, to $44.6 million from $46.1 million in the three month period ended March 31, 2023. The Company reported operating loss (as defined below) of $2.4 million in the three month period ended March”
JACK IN THE BOX INC reported second quarter fiscal 2024 ended April 14, 2024 results: revenue 365.3 million, net income 25.0 million, EPS 1.26.
“Earnings Per Share (2) , a non-GAAP measure, was $1.46 in the second quarter of fiscal 2024 compared with $1.47 in the prior year quarter. Total revenues decreased 7.7% to $365.3 million, compared to $395.7 million in the prior year quarter. The lower revenue is primarily the result of the Del Taco refranchising efforts. Net earnings was $25.0 million for the”
IMMUCELL CORP /DE/ reported the quarter ended March 31, 2024 results: revenue $7.3 million, net income Net loss was $438,000, EPS $0.06 per basic share.
“comparable period ended March 31, 2023. Total sales during the trailing twelve-month period ended March 31, 2024 were 33% above the comparable period ended March 31, 2023. The $7.3 million in sales recorded during the first quarter of 2024 represents an all-time quarterly sales record for the Company. The next highest quarter was $6 million recorded during the”
PSYCHEMEDICS CORP reported the first quarter ended March 31, 2024 results: revenue $5.4 million, net income $0.7 million, EPS $0.12 per share.
“The Company’s revenue for the quarter ended March 31, 2024, was $5.4 million versus $5.9 million for the quarter ended March 31, 2023, a decrease of 9%. Net loss for the quarter was $0.7 million, or $0.12 per share, compared to a net loss of $0.4 million, or $.07 per share, for the comparable quarter last year.”
KOPIN CORP reported first quarter ended March 30, 2024 results: revenue $10.0 million, net income ($32.5) million, EPS ($0.27) per share.
“Total revenues for the first quarter ended March 30, 2024, were $10.0 million, compared to $10.8 million for the first quarter ended April 1, 2023, a 7% decrease.”
AMERICAN SHARED HOSPITAL SERVICES reported first quarter ended March 31, 2024 results: revenue $5.2 million, EPS $0.02 per share.
“The first quarter marks a good start to the year, with revenue growth of 5.9% to $5.2 million, and gross margin of $2.1 million, a 12.3% increase from the comparable period, reflecting continued efficiencies and operating leverage from the sales increase. The gross margin percentage reached 41.1%, which is in line with our historical average and for the first quarter we earned $0.02 per share.”
INTRUSION INC reported the first quarter ended March 31, 2024 results: revenue $1.1 million, net income $(1.7) million, or $(0.94) per share, EPS $(0.94) per share.
“Revenue for the first quarter of 2024 was $1.1 million, a decrease of $0.2 million on both a sequential and year-over-year basis.”
TRIO-TECH INTERNATIONAL reported the third quarter and first nine months of fiscal 2024 results: revenue $10,398,000, net income $70,000, EPS $0.02 per diluted share.
“results for the third quarter and first nine months of fiscal 2024. Fiscal 2024 Third Quarter Results For the three months ended March 31, 2024, total revenue increased 6% to $10,398,000 compared to $9,842,000 for same quarter last year. Manufacturing segment revenue increased 62% to $4,813,000, compared to $2,963,000 for the same quarter last year. Distribution”
TOFUTTI BRANDS INC reported the fiscal quarter ended March 30, 2024 results: net income $303,000, EPS $0.06 per share.
“We incurred a net loss of $303,000, or $0.06 per share (basic and diluted) for the quarter ended March 30, 2024”
AMPCO PITTSBURGH CORP reported the three months ended March 31, 2024 results: revenue $110.2 million, net income $(2.7) million, or $(0.14) per share, EPS $(0.14) per share.
“Ampco-Pittsburgh Corporation (NYSE: AP) reported net sales of $110.2 million for the three months ended March 31, 2024, compared to $104.8 million for the three months ended March 31, 2023.”
HOME DEPOT, INC. reported first quarter of fiscal 2024 results: revenue $36.4 billion, net income $3.6 billion, EPS $3.63 per diluted share. Guidance reaffirmed.
“Quarter Fiscal 2024 Results; Reaffirms Fiscal 2024 Guidance ATLANTA, May 14, 2024 -- The Home Depot ® , the world's largest home improvement retailer, today reported sales of $36.4 billion for the first quarter of fiscal 2024, a decrease of 2.3% from the first quarter of fiscal 2023. Comparable sales for the first quarter of fiscal 2024 decreased 2.8%, and”
TENAX THERAPEUTICS, INC. reported first quarter ended March 31, 2024 results: net income $3.8 million.
“Tenax Therapeutics reported a net loss for the first quarter of 2024 of $3.8 million”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.